Fierce Biotech April 22, 2024
Boehringer Ingelheim is making yet another bet that RNA therapies hold the key to treating metabolic-associated steatohepatitis (MASH).
The German drugmaker is paying British biotech Ochre Bio $35 million in upfront and near-term research-based milestone payments to investigate “multiple targets” for chronic liver disease. Top of the list of indications will be MASH, previously known as nonalcoholic steatohepatitis (NASH).
Should any of the targets in the “multi-year” collaboration prove fruitful, Ochre is also in line for various clinical, regulatory and commercial milestones as well as tiered royalties, which add up to a deal value north of $1 billion.
Ochre’s remit is developing RNA therapies that enhance the liver’s regenerative capabilities in order to halt or reverse chronic liver diseases. It’s...
Today's Sponsors
Today's Sponsor